|Alma mater||Claude Bernard University Lyon 1|
|Institutions||South Lyon Hospital Complex, Lyon, France|
Gilles Salles is a French University Professor, Medical Doctor and a specialist in haematological oncology, notably lymphomas. He is one of the most cited European scientists in the areas of haematology and lymphoma.
Salles is the head of the Steering Committee of the CALYM consortium.
He has obtained his master DEA degree in Differentiation, Genetics and Immunology from the Claude Bernard University of Lyon in 1986. In 1989 he continued his university studies and graduated as a Doctor of Medicine, in 1992 he obtained an Advanced Specialised Studies Degree in Cancerology. 1994 he defended his thesis in immunology on the Signals that regulate the formation of B lymphocytes. He has completed his post-doctorate fellowship at the Dana Farber Cancer Institute of the Harvard Medical School of Boston in the United States.
Since 1996, he is the head of the research team “Indolent B-cell proliferation” currently affiliated with the Laboratoire de Biologie Moléculaire de la Cellule (UMR5239 : ENS-Lyon, CNRS, Université Claude Bernard, Hospices Civils de Lyon), that examines several aspects of lymphoma biology (senescence and apoptosis in lymphocytes, biology of splenic marginal zone, prognostic factors in lymphoma).
Previous he also held the Chair of the Leukaemia Committee of the “Fondation de France” (2005–07) and the Chair of the Scientific Programme Committee of the European Hematology Association (EHA) for its 13th Congress (2008).
At the moment Gilles Salles holds the following positions: - Professor of Medicine (Haematology) at Université Lyon-1, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux (1996) - Chair of the Clinical Haematology Department at the Hospices Civils de Lyon (Centre Hospitalier Lyon-Sud) (2011) - Chair of the research team “Indolent B-cell proliferation” in the LBMC - UMR 5239 (ENS - CNRS – UCB - HCL) (2007) - Chair of the LYSA cooperative group (leading cooperative group in lymphoma research) (2012) - Vice-president in charge of research at the board of Directors of the Hospices Civils de Lyon (2010) - Member of the Editorial Board of Blood (2014) - Head of the Steering Committee of the CALYM consortium
He is also a member of several professional societies, including the American Society of Hematology
Salles has been especially interested in the clinical and biological study of malignant lymphoma – major focuses of his work include the description and validation of prognostic factors as well as clinical trials in indolent lymphomas. He has been involved as a coordinator or co-investigator in many clinical trials and studies within his field. Gilles Salles has led a phase I/II study of rituximab, the antibody that is used most often in the treatment of lymphoma.
Salles is the author of 303 publications.
- Controversies in Indolent Lymphoma at American Society of Clinical Oncology Annual Meeting
- New Evidence, On Follicular Lymphoma
- Revision of the Clinical Trials: No time to waste
- Small Molecules Bring Hope for Follicular Lymphoma Patients
- GPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. opal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA.; N Engl J Med. 2014 370(11):1008-18 (A)
- Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica; Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d’Etude des Lymphomes de l’Adulte (GELA); 2013 98(7):1107-14. (A)
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study; Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G; J Clin Oncol. 2013 ;31(23):2920-6 (A)
- Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms; Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G. ; Blood. 2012;120(13):2650-7.
- Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial; Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. ; Lancet. 2011 Nov 26;378(9806):1858-67.
- Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.; Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, Pettengell R, Witzens-Harig M, Shpilberg O. ; J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806.
- Early steps of follicular lymphoma pathogenesis.; Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B. ; Adv Immunol. 2011;111:1-46.
- Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.; Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. ; J Clin Oncol. 2011 Aug 10;29(23):3194-200.
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.; Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E. ; Blood. 2011 Jun 30;117(26):7070-8.
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.; Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. ; Lancet. 2011 Jan 1;377(9759):42-51.
- https://scholar.google.fr. Google Scholar https://scholar.google.fr/citations?view_op=search_authors&mauthors=gilles+salles&hl=en&oi=ao. Missing or empty
|title=(help); External link in
- "The teams". Fondation Synergie. Retrieved 10 June 2014.
|last1=in Authors list (help)
- "Obinutuzumab (GA101), a New Generation Rituximab". http://cornell-lymphoma.com. New Developments in Lymphoma. Retrieved 10 June 2014. External link in
- "Rituximab and other antibodies in the treatment of lymphoma" (PDF). www.lymphomas.org.uk. Lymphoma Association.
|last1=in Authors list (help)
- Template:Pubmed, ISI-h index: 49